

Boehringer Ingelheim Is Pleased to  
Invite You to Join Our Virtual Symposium



## Disrupting Cancer's Operating Functions

Sunday, 19 September 2021 at 18:45-20:15 (CEST) on Channel 5  
Then on-demand until 28 September 2021

Watch an international panel of experts present advances in the development of therapies that may:

- Control *KRAS* and dampen overactive oncogenic drivers, such as HER2 exon 20
- Alter the outcomes of rare tumors by reactivating p53 through MDM2 inhibition
- Deliver the promise of immuno-oncology through smart I-O combinations and novel technologies, such as oncolytic viruses and T-cell engagers

<b>Welcome and Introduction</b>	5 min	<b>Chair: Egbert Smit</b> <i>Netherlands Cancer Institute, VU University Medical Center Amsterdam, Netherlands</i>
<b>Controlling Cancer Cell Hallmarks to Deliver Breakthrough Therapies</b>	20 min	<b>Egbert Smit</b> <i>Netherlands Cancer Institute, VU University Medical Center Amsterdam, Netherlands</i>
<b>Altering Outcomes for Rare Tumors With New Treatment Options</b>	20 min	<b>Mrinal Gounder</b> <i>Memorial Sloan Kettering Cancer Center New York, USA</i>
<b>Rebooting Checkpoint Inhibition With Smart Combinations</b>	20 min	<b>Hossein Borghaei</b> <i>Fox Chase Cancer Center Philadelphia, USA</i>
<b>Deleting Tumors Through Novel Approaches to Ramp Up the Immune System</b>	20 min	<b>Ulrich Lauer</b> <i>Eberhard Karls University Tübingen, Germany</i>
<b>Closing: Key Takeaways</b>	5 min	<b>Chair: Egbert Smit</b> <i>Netherlands Cancer Institute, VU University Medical Center Amsterdam, Netherlands</i>

LET'S COLLABORATE  
ONCOLOGY FROM BOEHRINGER INGELHEIM

